Trastuzumab Deruxtecan in HER2-Low Breast Cancer. Reply

N Engl J Med. 2022 Sep 22;387(12):1145-1146. doi: 10.1056/NEJMc2210368.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Breast Neoplasms* / drug therapy
  • Camptothecin / analogs & derivatives
  • Female
  • Humans
  • Immunoconjugates*
  • Trastuzumab / therapeutic use

Substances

  • Immunoconjugates
  • trastuzumab deruxtecan
  • Trastuzumab
  • Camptothecin